STRATEGIC HEALTH SOLUTIONS

Lobbying Income

$5.0M

Filings

126

Unique Clients

Active Period

2002–2006

Lobbying Income by Year

Registrant-reported income from clients on LDA filings

Year	Lobbying Income	Filings	Clients
2006	$1,494,100	21	13
2005	$696,000	13	8
2004	$1,006,197	22	16
2003	$1,278,386	57	17
2002	$519,342	13	13

Largest clients by registrant-reported income

Client	Reported Income	Filings	Period
CARDINAL HEALTH	$670,854	8	2002–2006
HEALTHCARE LEADERSHIP COUNCIL	$442,487	9	2002–2006
BIOGEN-IDEC	$397,606	8	2003–2006
HOFFMAN-LAROCHE	$371,602	6	2002–2006
SPECIALTY PHARMACY COALITION	$360,000	5	2004–2006
BONE GROWTH STIMULATOR COALITION	$360,000	5	2005–2006
ELI LILLY & CO	$277,593	6	2002–2004
CAREMARK RX	$254,483	7	2002–2004
AMGEN, INC.	$221,307	6	2002–2004
NATL ORTHOTIC MANUFACTURERS ASSN	$209,491	8	2002–2006
AVENTIS INC	$200,000	3	2005–2006
ASSN OF COMMUNITY CANCER CENTERS	$190,517	7	2002–2004
ORGANOGENESIS	$180,026	6	2003–2006
ASTRAZENECA PHARMACEUTICALS	$180,000	3	2004–2006
JOINT COMMISSION ON ACCREDITATION OF HEALTHCARE ORGS	$167,245	6	2002–2006
NOVARTIS	$118,738	5	2002–2003
GUILFORD PHARMACEUTICALS	$93,057	6	2002–2004
DEROYAL INDUSTRIES INC	$81,461	5	2003–2004
AMERICAN CLINICAL LABORATORY ASSN	$75,000	4	2003–2006
FIDELITY INVESTMENTS	$70,000	7	2002–2004
NATL COALITION FOR ASSISTIVE & REHAB TECHNOLOGY	$50,000	2	2006
POWELL GOLDSTEIN FRAZER & MURPHY	$22,558	4	2002–2003

Government entities explicitly identified as targets in LDA filings

Government Body	Filings
HOUSE OF REPRESENTATIVES	90
SENATE	90
Centers For Medicare and Medicaid Services (CMS)	1

Most frequently reported lobbying issues

Issue Code	Description	Reports
Health Issues	Health Issues	96
Medicare/Medicaid	Medicare/Medicaid	25
Pharmacy	Pharmacy	7
Science/Technology	Science/Technology	1
Manufacturing	Manufacturing	1
Medical/Disease Research/Clinical Labs	Medical/Disease Research/Clinical Labs	1

STRATEGIC HEALTH SOLUTIONS — Lobbying Disclosure | Poliscope